Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...
Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET In this video The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant ...
Pharma trade organisations in the US have told President Trump that tariffs such as the 10% levy on Chinese imports could drive up the cost of generic medicines, impact supply chains, and exacerbate ...
Tensions in the Strait of Hormuz are raising alarms about the stability of global pharmaceutical supply chains, with potential implications for the U.S. generic drug market, which relies heavily on ...
Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...
Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of Hormuz for the arrival of key inputs in drug manufacturing including petroleum-based materials, and for ...
The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with obesity. The new dose showed greater weight loss in a large clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results